The startup has developed a preclinical cell therapy platform that produces primary human hepatocytes (HHCs) for drug toxicology studies and liver disease research. This technology provides a reliable source of functional liver cells, which are essential for testing therapies for acute, chronic, and rare liver conditions.
Funding
$13.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatment options for liver disease are limited, and the availability of primary human hepatocytes (HHCs) for research and therapeutic applications is restricted by inconsistent supply and quality. This scarcity hinders advancements in drug discovery, disease modeling, and the development of cell-based therapies for liver failure and related conditions.
Solution
Cytotheryx is developing a preclinical cell therapy platform that utilizes a proprietary bio-incubator to produce a consistent, high-quality supply of primary human hepatocytes. This platform enables the scalable expansion of HHCs while maintaining their vital liver functions, addressing the unmet need for reliable and functional liver cells. The expanded supply of HHCs facilitates applications in preclinical drug discovery, disease-specific research, liver assist devices, cell therapy, and other innovative treatments for liver disease, liver failure, and rare diseases. Cytotheryx's technology aims to provide a new gold standard for toxicology and metabolic studies in drug development and to enable novel therapeutic interventions for liver-related disorders.
Target Audience
The primary target audience includes researchers in drug discovery and disease modeling, as well as clinicians and biotechnology companies focused on developing cell-based therapies for liver diseases.
Features
- Proprietary bio-incubator technology for scalable expansion of primary human hepatocytes
- Consistent production of high-quality, functional liver cells
- Enhanced supply of HHCs for research and therapeutic applications
- Support for drug metabolism and toxicity studies
- Facilitation of disease modeling and regenerative medicine research
- Potential for cell therapy, bioartificial liver devices, and hepatocyte transplantation
- Opportunities for genetic engineering and personalized medicine approaches